Women in the UK suffering from endometriosis may soon experience significantly reduced waiting times for diagnosis following the National Institute for Health and Care Excellence (Nice) approval of two new non-invasive tests. The Endotest and EndoSure tests, now recommended for use on the National Health Service (NHS) for an initial three-year period, aim to drastically cut down the average diagnostic delay, which currently stands at over nine years. This development could offer a 'game-changing' solution for the estimated one in ten women of reproductive age affected by the painful condition.
The Endotest involves a simple saliva sample that is analyzed in a laboratory for specific biological markers called microRNAs, which indicate the presence of endometriosis. The EndoSure test measures electrical signals in the gut using sensor pads placed on the abdomen. For this test, patients fast for six to eight hours and then drink water for 45 minutes.
Addressing Diagnostic Delays
Currently, diagnosing endometriosis often involves invasive procedures like laparoscopy, alongside imaging such as ultrasound scans and MRIs. However, delays are common due to factors including the availability of expert medical professionals and long waiting lists for gynecological services. A survey of over 10,000 women revealed that more than half visited their GP more than ten times before receiving a diagnosis, with a similar percentage seeking emergency care for their symptoms.
Dr. Anastasia Chalkidou, healthtech program director at Nice, highlighted the profound impact of these delays. "A diagnosis of endometriosis can for some women take the best part of a decade, with the UK average standing at nine years and four months, and rising to 11 years for those from ethnically diverse communities," she stated. "That delay means living with chronic pelvic pain that affects daily life, relationships and work." She added that these new technologies offer the potential to equip primary care professionals with better non-invasive tools for earlier identification, leading to quicker and more effective treatment.
How the Tests Work
While neither test is intended as a standalone diagnostic tool, they are designed to help identify potential cases earlier, facilitating faster referral for diagnosis and treatment. The Endotest provides laboratory results that inform the GP's next steps, whereas EndoSure offers results immediately after the test is completed. Nice recommends these tests for women where endometriosis is suspected despite normal clinical examinations and inconclusive or negative imaging results, or when imaging has not been utilized.
Scientists have also identified a distinct hormonal 'signature' in individuals with endometriosis. Research led by the University of Edinburgh found differences in a group of androgens, often referred to as 'male' hormones, among those with the condition. By analyzing hormone levels in blood samples, researchers were able to correctly identify over 95% of participants with endometriosis. This discovery could pave the way for even simpler, non-invasive diagnostic methods in the future.
Patient accounts underscore the significance of timely diagnosis. Simran Chavda, 15, recounted years of severe pelvic pain and repeated medical visits that failed to identify the cause, with many suspecting irritable bowel syndrome. "Getting my diagnosis honestly felt like the best thing in the world," she said. "When I finally found out what it was, I was so relieved because now I knew what the next step was."
Dr. Gail Busby, consultant gynecologist, emphasized the transformative potential of these tests. "These tests are a game-changer because they give us answers much earlier, without the need for invasive surgery, and that means we can start the right treatment sooner," she explained. "An earlier diagnosis doesn't just change one person's life, it frees up appointments and surgical slots for everyone waiting for care."